1. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Issue 10097 (26th August 2017) Authors: Russell, Stephen; Bennett, Jean; Wellman, Jennifer A; Chung, Daniel C; Yu, Zi-Fan; Tillman, Amy; Wittes, Janet; Pappas, Julie; Elci, Okan; McCague, Sarah; Cross, Dominique; Marshall, Kathleen A; Walshire, Jean; Kehoe, Taylor L; Reichert, Hannah; Davis, Maria; Raffini, Leslie; George, Lindsey A; H... Journal: Lancet Issue: Volume 390:Issue 10097(2017) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗